Nutriband Inc
NTRB
Company Profile
Business description
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Contact
121 South Orange Avenue
Suite 1500
OrlandoFL32801
USAT: +1 407 377-6695
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 January 2027
Employees
3
Stocks News & Analysis
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,657.50 | 2.20 | 0.03% |
| CAC 40 | 7,732.77 | 30.82 | 0.40% |
| DAX 40 | 22,359.27 | 58.52 | 0.26% |
| Dow JONES (US) | 45,298.08 | 131.44 | 0.29% |
| FTSE 100 | 10,073.06 | 105.71 | 1.06% |
| HKSE | 24,750.79 | 201.09 | -0.81% |
| NASDAQ | 20,923.88 | 24.47 | -0.12% |
| Nikkei 225 | 51,885.85 | 1,487.22 | -2.79% |
| NZX 50 Index | 12,748.92 | 186.47 | -1.44% |
| S&P 500 | 6,373.28 | 4.43 | 0.07% |
| S&P/ASX 200 | 8,461.00 | 0.10 | 0.00% |
| SSE Composite Index | 3,923.29 | 9.56 | 0.24% |